

Research Grants

- 2016-2021 CIHR. Co-applicant with S. Villeneuve (PI), J. Breitner, J. Poirier, P. Rosa-Neto, A. Evans. \$710,985 (total). *Towards a better understanding of the impact of vascular health on Alzheimer's disease pathology and clinical expression*
- 2016-2021 CIHR. Co-applicant with H. Chertkow (PI). \$4,750,000. *Team grant: new directions in dementia research: big data on dementia.*
- 2017-2022 CIHR. Co-applicant with N. Rajah (PI). \$833,850. *The impact of sex, menopausal status and +APOE4 risk for Alzheimer's disease on the neural correlates of episodic memory in healthy middle-aged adults*
- 2017-2023 CIHR. Co-applicant with J. Carrier & J. Montplaisir. \$665,550. *Quantitative electroencephalography in rapid-eye-movement (REM) sleep: an early marker of cholinergic neurodegeneration in mild cognitive impairment*
- 2018-2020 Weston Brain Institute. Co-applicant with P. Rosa-Neto (PI). \$1,527,750. *In vivo qualification of tau aggregates as a measure of disease progression in AD spectrum.*
- 2018-2021 CIHR. Co-PI with P. Rosa-Neto. \$1,262,250. *Imaging epigenetics in dementia.*
- 2018-2023 CIHR. Co-applicant with S. Villeneuve (PI). \$1,059,525. *Preventing the progression of Alzheimer's disease pathology by targeting the effects of lifestyle factors and personality traits*
- 2019-2022 CIHR. Co-applicant with H. Chertkow (PI) et al. *CCNA Phase II.* \$46,222 per year.
- 2019-2020 Weston Brain Institute. Co-applicant with P. Rosa-Neto (PI). *Novel biomarkers for PSP: a pilot study.* \$297,000.
- 2019-2024 FRSQ. Co-PI with P. Rosa-Neto. *Biomarqueurs de vieillissement et de démence : BioVie* \$280,000 à \$297,513/an, total \$1,442,842.00.
- 2021-2022 Alzheimer Disease International. *World Alzheimer Reports 2021 and 2022.* US\$100,000